# NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

> **NCT02689921** · PHASE2 · UNKNOWN · sponsor: **Midwestern Regional Medical Center** · enrollment: 7 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Exemestane
- **DRUG:** Letrozole
- **DRUG:** Anastrozole
- **DRUG:** Leuprolide Acetate
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02689921
- **Lead sponsor:** Midwestern Regional Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2018-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02689921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02689921, "NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02689921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*